Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

Our detailed focused library is generated on demand with advanced virtual screening and parameter assessment technology powered by the Receptor.AI drug discovery platform. This method surpasses traditional approaches, delivering compounds of better quality with enhanced activity, selectivity, and safety.


We pick out particular compounds from an extensive virtual database of more than 60 billion molecules. The preparation and shipment of these compounds are facilitated by Reaxense.


The library includes a list of the most promising modulators annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Also, each compound is presented with its optimal docking poses, affinity scores, and activity scores, providing a comprehensive overview.


Our high-tech, dedicated method is applied to construct targeted libraries for enzymes.


 

Fig. 1. The screening workflow of Receptor.AI

The procedure entails thorough molecular simulations of the catalytic and allosteric binding pockets, accompanied by ensemble virtual screening that factors in their conformational flexibility. When developing modulators, the structural modifications brought about by reaction intermediates are factored in to optimize activity and selectivity.


Our library is unique due to several crucial aspects:


  • Receptor.AI compiles all relevant data on the target protein, such as past experimental results, literature findings, known ligands, and structural data, thereby enhancing the likelihood of focusing on the most significant compounds.

  • By utilizing advanced molecular simulations, the platform is adept at locating potential binding sites, rendering the compounds in the focused library well-suited for unearthing allosteric inhibitors and binders for hidden pockets.

  • The platform is supported by more than 50 highly specialized AI models, all of which have been rigorously tested and validated in diverse drug discovery and research programs. Its design emphasizes efficiency, reliability, and accuracy, crucial for producing focused libraries.

  • Receptor.AI extends beyond just creating focused libraries; it offers a complete spectrum of services and solutions during the preclinical drug discovery phase, with a success-dependent pricing strategy that reduces risk and fosters shared success in the project.


PARTNER
Receptor.AI
 
UPACC
Q8WXG1

UPID:
RSAD2_HUMAN

ALTERNATIVE NAMES:
Cytomegalovirus-induced gene 5 protein; Radical S-adenosyl methionine domain-containing protein 2; Virus inhibitory protein, endoplasmic reticulum-associated, interferon-inducible

ALTERNATIVE UPACC:
Q8WXG1; Q8WVI4

BACKGROUND:
The protein RSAD2, with alternative names such as Radical S-adenosyl methionine domain-containing protein 2, is crucial for the cell's antiviral response. It inhibits the replication of numerous viruses by generating ddhCTP, which halts viral RNA polymerases. RSAD2 also plays a role in immune system activation, including promoting TLR7 and TLR9-dependent IFN-beta production and facilitating T-cell differentiation.

THERAPEUTIC SIGNIFICANCE:
Exploring the multifunctional role of RSAD2 offers a promising avenue for the discovery of novel antiviral and immunotherapeutic drugs, leveraging its broad-spectrum antiviral activity and immunomodulatory functions.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.